Finance
Finance
MwanzoDRREDDY • NSE
Dr Reddy's Laboratories Ltd
₹ 1,314.00
12 Sep, 15:58:24 GMT +5:30 · INR · NSE · Kanusho
HisaHisa zinazouzwa INMakao yake makuu ni IN
Bei iliyotangulia
₹ 1,303.10
Bei za siku
₹ 1,302.80 - ₹ 1,321.00
Bei za mwaka
₹ 1,020.00 - ₹ 1,405.90
Thamani ya kampuni katika soko
1.09T INR
Wastani wa hisa zilizouzwa
1.35M
Uwiano wa bei na mapato
19.28
Mgao wa faida
0.61%
Ubadilishanaji wa msingi
NSE
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
(INR)Jun 2025Mabadiliko Tangu Mwaka Uliopita
Mapato
85.45B11.37%
Matumizi ya uendeshaji wa biashara
31.11B9.43%
Mapato halisi
14.18B1.85%
Kiwango cha faida halisi
16.59-8.54%
Mapato kwa kila hisa
17.021.94%
EBITDA
22.28B2.56%
Asilimia ya kodi ya mapato
25.99%
Jumla ya mali
Jumla ya dhima
(INR)Jun 2025Mabadiliko Tangu Mwaka Uliopita
Uwekezaji wa pesa taslimu na vipindi vifupi
66.69B-29.52%
Jumla ya mali
519.54B25.10%
Jumla ya dhima
165.78B37.38%
Jumla ya hisa
353.76B
hisa zilizosalia
832.37M
Uwiano wa bei na thamani
3.10
Faida inayotokana na mali
8.65%
Faida inayotokana mtaji
11.14%
Mabadiliko halisi ya pesa taslimu
(INR)Jun 2025Mabadiliko Tangu Mwaka Uliopita
Mapato halisi
14.18B1.85%
Pesa kutokana na shughuli
14.63B72.19%
Pesa kutokana na uwekezaji
-19.19B5.22%
Pesa kutokana na ufadhili
-1.20B-112.61%
Mabadiliko halisi ya pesa taslimu
-5.59B-154.74%
Mtiririko huru wa pesa
1.99B714.35%
Kuhusu
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology. Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe. By 2007, Dr. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
1984
Wafanyakazi
27,811
Gundua zaidi
Huenda unavutiwa na
Orodha hii imetokana na maudhui uliyotafuta hivi majuzi, hisa unazofuatilia na shughuli zingine. Pata maelezo zaidi

Data na maelezo yote hutolewa “kama yalivyo” kwa madhumuni ya taarifa binafsi tu, wala hayanuii kuwa ushauri wa kifedha na hayana madhumuni ya kufanya biashara au uwekezaji, kodi, kisheria, uhasibu au ushauri mwingine. Google si mshauri wa uwekezaji wala mshauri wa kifedha na haitoi maoni au mapendekezo yanayohusiana na kampuni zozote zilizojumuishwa kwenye orodha hii au hisa zozote zilizotolewa na kampuni hizo. Tafadhali wasiliana na dalali wako au mwakilishi wa kifedha ili uthibitishe bei kabla ya kufanya biashara yoyote. Pata maelezo zaidi
Watu pia hutafuta
Tafuta
Futa utafutaji
Funga kisanduku cha kutafutia
Programu za Google
Menyu kuu